Increased risk of vascular complications in Takayasu's arteritis patients with positive lupus anticoagulant

Objectives: Previous studies have shown antiphospholipid antibodies (aPL) to be prevalent in primary systemic vasculitides; however, the possible clinical impact of aPL positivity in such patients has not been explored in depth. The aims of this study were to determine the prevalence of aPL in patie...

Full description

Saved in:
Bibliographic Details
Published inScandinavian journal of rheumatology Vol. 44; no. 3; pp. 211 - 214
Main Authors Jordan, NP, Bezanahary, H, D'Cruz, DP
Format Journal Article
LanguageEnglish
Published England Informa Healthcare 01.05.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objectives: Previous studies have shown antiphospholipid antibodies (aPL) to be prevalent in primary systemic vasculitides; however, the possible clinical impact of aPL positivity in such patients has not been explored in depth. The aims of this study were to determine the prevalence of aPL in patients with Takayasu's arteritis (TA) and to ascertain whether aPL positivity was predictive of a worse clinical outcome in TA. Method: Clinical data were collected retrospectively on 22 TA patients over an 11-year period. Data collected included the presence of lupus anticoagulant (LA) and immunoglobulin (Ig)G and IgM anticardiolipin antibody (aCL) titres. Adverse clinical outcomes included cerebrovascular accident (CVA), transient ischaemic attack (TIA), loss of vision, vascular lesions (carotid, femoral, renal, coronary, or other vessels) requiring stenting, angioplasty, or other surgical intervention, aortic valve replacement, end-stage renal failure or death. Results: Persistently positive aPL or a concurrent diagnosis of antiphospholipid syndrome (APS) was found in 45% (n = 10) of TA patients while 55% (n = 12) had TA alone. LA was present in a significant proportion of TA patients with aPL (p = 0.002). Vascular complications occurred in 70% (n = 7) of TA patients with aPL and in 25% (n = 3) of TA patients without aPL (p = 0.035). LA was associated with a higher prevalence of vascular complications. Conclusions: Persistently positive aPL are present in a significant proportion of TA patients. This study shows that vascular complications and need for intervention are more prevalent in TA patients with aPL, particularly those with LA. Prospective studies are needed to determine the long term prognosis in such patients.
AbstractList Objectives: Previous studies have shown antiphospholipid antibodies (aPL) to be prevalent in primary systemic vasculitides; however, the possible clinical impact of aPL positivity in such patients has not been explored in depth. The aims of this study were to determine the prevalence of aPL in patients with Takayasu's arteritis (TA) and to ascertain whether aPL positivity was predictive of a worse clinical outcome in TA. Method: Clinical data were collected retrospectively on 22 TA patients over an 11-year period. Data collected included the presence of lupus anticoagulant (LA) and immunoglobulin (Ig)G and IgM anticardiolipin antibody (aCL) titres. Adverse clinical outcomes included cerebrovascular accident (CVA), transient ischaemic attack (TIA), loss of vision, vascular lesions (carotid, femoral, renal, coronary, or other vessels) requiring stenting, angioplasty, or other surgical intervention, aortic valve replacement, end-stage renal failure or death. Results: Persistently positive aPL or a concurrent diagnosis of antiphospholipid syndrome (APS) was found in 45% (n = 10) of TA patients while 55% (n = 12) had TA alone. LA was present in a significant proportion of TA patients with aPL (p = 0.002). Vascular complications occurred in 70% (n = 7) of TA patients with aPL and in 25% (n = 3) of TA patients without aPL (p = 0.035). LA was associated with a higher prevalence of vascular complications. Conclusions: Persistently positive aPL are present in a significant proportion of TA patients. This study shows that vascular complications and need for intervention are more prevalent in TA patients with aPL, particularly those with LA. Prospective studies are needed to determine the long term prognosis in such patients.
OBJECTIVESPrevious studies have shown antiphospholipid antibodies (aPL) to be prevalent in primary systemic vasculitides; however, the possible clinical impact of aPL positivity in such patients has not been explored in depth. The aims of this study were to determine the prevalence of aPL in patients with Takayasu's arteritis (TA) and to ascertain whether aPL positivity was predictive of a worse clinical outcome in TA. METHODClinical data were collected retrospectively on 22 TA patients over an 11-year period. Data collected included the presence of lupus anticoagulant (LA) and immunoglobulin (Ig)G and IgM anticardiolipin antibody (aCL) titres. Adverse clinical outcomes included cerebrovascular accident (CVA), transient ischaemic attack (TIA), loss of vision, vascular lesions (carotid, femoral, renal, coronary, or other vessels) requiring stenting, angioplasty, or other surgical intervention, aortic valve replacement, end-stage renal failure or death. RESULTSPersistently positive aPL or a concurrent diagnosis of antiphospholipid syndrome (APS) was found in 45% (n = 10) of TA patients while 55% (n = 12) had TA alone. LA was present in a significant proportion of TA patients with aPL (p = 0.002). Vascular complications occurred in 70% (n = 7) of TA patients with aPL and in 25% (n = 3) of TA patients without aPL (p = 0.035). LA was associated with a higher prevalence of vascular complications. CONCLUSIONSPersistently positive aPL are present in a significant proportion of TA patients. This study shows that vascular complications and need for intervention are more prevalent in TA patients with aPL, particularly those with LA. Prospective studies are needed to determine the long term prognosis in such patients.
Previous studies have shown antiphospholipid antibodies (aPL) to be prevalent in primary systemic vasculitides; however, the possible clinical impact of aPL positivity in such patients has not been explored in depth. The aims of this study were to determine the prevalence of aPL in patients with Takayasu's arteritis (TA) and to ascertain whether aPL positivity was predictive of a worse clinical outcome in TA. Clinical data were collected retrospectively on 22 TA patients over an 11-year period. Data collected included the presence of lupus anticoagulant (LA) and immunoglobulin (Ig)G and IgM anticardiolipin antibody (aCL) titres. Adverse clinical outcomes included cerebrovascular accident (CVA), transient ischaemic attack (TIA), loss of vision, vascular lesions (carotid, femoral, renal, coronary, or other vessels) requiring stenting, angioplasty, or other surgical intervention, aortic valve replacement, end-stage renal failure or death. Persistently positive aPL or a concurrent diagnosis of antiphospholipid syndrome (APS) was found in 45% (n = 10) of TA patients while 55% (n = 12) had TA alone. LA was present in a significant proportion of TA patients with aPL (p = 0.002). Vascular complications occurred in 70% (n = 7) of TA patients with aPL and in 25% (n = 3) of TA patients without aPL (p = 0.035). LA was associated with a higher prevalence of vascular complications. Persistently positive aPL are present in a significant proportion of TA patients. This study shows that vascular complications and need for intervention are more prevalent in TA patients with aPL, particularly those with LA. Prospective studies are needed to determine the long term prognosis in such patients.
Author D'Cruz, DP
Jordan, NP
Bezanahary, H
Author_xml – sequence: 1
  givenname: NP
  surname: Jordan
  fullname: Jordan, NP
  email: natasha.4.jordan@kcl.ac.uk, natasha.4.jordan@kcl.ac.uk
  organization: Louise Coote Lupus Unit, St Thomas' Hospital
– sequence: 2
  givenname: H
  surname: Bezanahary
  fullname: Bezanahary, H
  email: natasha.4.jordan@kcl.ac.uk, natasha.4.jordan@kcl.ac.uk
  organization: Louise Coote Lupus Unit, St Thomas' Hospital
– sequence: 3
  givenname: DP
  surname: D'Cruz
  fullname: D'Cruz, DP
  email: natasha.4.jordan@kcl.ac.uk, natasha.4.jordan@kcl.ac.uk
  organization: Louise Coote Lupus Unit, St Thomas' Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25438797$$D View this record in MEDLINE/PubMed
BookMark eNp9kMFu1DAQhi1URLeFN0DIN7hksWNvnFxAqCpQqVIv7dmatR3W3cQOHqfVvn0dbYvEpaeRZr75Z_SdkZMQgyPkI2drwVn3lQnGOiXrdc24XHeNFGzzhqz4htWVUqI-IasFqRbmlJwh3jPGZKe6d-S03kjRqk6tyP4qmOQAnaXJ457Gnj4AmnmARE0cp8EbyD4GpD7QW9jDAXD-jBRSdslnj3Qqcxcy0kefd3SKWLoPjg7zNBcsZG8i_Cl5Ib8nb3sY0H14rufk7ufl7cXv6vrm19XFj-vKSN7minetdZJbqZTbSsZrUK6VLedbK0VjOWdNVzcOjJCmsa0VSjXAlOhFa5WSIM7Jl2PulOLf2WHWo0fjhvKDizNq3rRMlcBuU1B5RE2KiMn1ekp-hHTQnOlFs37RrBfN-qi5rH16vjBvR2f_Lb14LcD3I-BDH9MIjzENVmc4DDH1CYLxuMS_euLbfwk7B0PeGUhO38c5hSLw9R-fAPMPoqg
CitedBy_id crossref_primary_10_15829_1728_8800_2019_5_90_97
crossref_primary_10_1007_s10067_023_06552_5
crossref_primary_10_1007_s40272_019_00327_9
crossref_primary_10_5692_clinicalneurol_cn_000815
crossref_primary_10_1097_MD_0000000000002345
crossref_primary_10_1136_rmdopen_2019_001020
crossref_primary_10_3390_diagnostics11111997
crossref_primary_10_3389_fcvm_2021_603354
crossref_primary_10_1136_bcr_2015_211752
crossref_primary_10_1007_s00296_023_05440_0
crossref_primary_10_1007_s00415_018_8744_8
crossref_primary_10_3390_life12111904
crossref_primary_10_1007_s00296_016_3435_1
crossref_primary_10_1016_j_rcreue_2017_07_004
crossref_primary_10_1016_j_rcreu_2017_07_004
Cites_doi 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
10.1007/s10067-006-0277-3
10.1080/03009740510026526
10.1136/ard.2004.034231
10.1002/1529-0131(200002)43:2<440::AID-ANR26>3.0.CO;2-N
10.1002/art.1780330811
10.1002/art.22404
10.1007/s00296-005-0065-4
ContentType Journal Article
Copyright 2015 Taylor & Francis on license from Scandinavian Rheumatology Research Foundation 2015
2015 Informa Healthcare on license from Scandinavian Rheumatology Research Foundation 2015
Copyright_xml – notice: 2015 Taylor & Francis on license from Scandinavian Rheumatology Research Foundation 2015
– notice: 2015 Informa Healthcare on license from Scandinavian Rheumatology Research Foundation 2015
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.3109/03009742.2014.964305
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1502-7732
EndPage 214
ExternalDocumentID 10_3109_03009742_2014_964305
25438797
964305
Genre Articles
Journal Article
GroupedDBID ---
.GJ
00X
03L
08R
0BK
0R~
123
34G
36B
39C
3O-
4.4
53G
5RE
5VS
AAJNR
AALIY
AALUX
AAMIU
AAPUL
AAPXX
AAQRR
AAWTL
ABBKH
ABDBF
ABEIZ
ABLKL
ABPTK
ABUPF
ABWCV
ABZEW
ACENM
ACFUF
ACGEJ
ACGFO
ACGFS
ACKZS
ACLSK
ADCVX
ADFCX
ADFOM
ADFZZ
ADRBQ
ADXPE
AECIN
AEGXH
AEIIZ
AENEX
AEOZL
AEYQI
AFFNX
AFKVX
AFLEI
AFWLO
AGDLA
AGFJD
AGRBW
AGYJP
AIAGR
AIJEM
AIRBT
AJVHN
AJWEG
AKBVH
ALIIL
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AMDAE
AWYRJ
BABNJ
BLEHA
BOHLJ
BRMBE
CAG
CCCUG
COF
CS3
CYYVM
CZDIS
DKSSO
DRXRE
DU5
DWTOO
EAP
EBB
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
H13
HZ~
J.N
J5H
JENTW
KRBQP
KSSTO
KWAYT
KYCEM
L7B
LJTGL
M44
M4Z
O9-
OVD
P2P
QQXMO
RNANH
RVRKI
SV3
TEORI
TFDNU
TFL
TFW
TUS
UEQFS
V1S
ZGI
ZXP
~1N
AAORF
ABJNI
ABLIJ
ABXYU
ACIEZ
ALYBC
CGR
CUY
CVF
ECM
EIF
NPM
NUSFT
TBQAZ
TDBHL
TERGH
TUROJ
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c418t-198de41d477eb4012a7e84811bd436d1106926eac34c6d8d3776a073f38d774a3
ISSN 0300-9742
IngestDate Fri Aug 16 04:05:41 EDT 2024
Fri Aug 23 02:15:02 EDT 2024
Wed Oct 16 00:45:25 EDT 2024
Tue Jun 13 19:59:54 EDT 2023
Wed Jun 21 08:18:10 EDT 2023
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c418t-198de41d477eb4012a7e84811bd436d1106926eac34c6d8d3776a073f38d774a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 25438797
PQID 1680748195
PQPubID 23479
PageCount 4
ParticipantIDs informaworld_taylorfrancis_310_3109_03009742_2014_964305
pubmed_primary_25438797
proquest_miscellaneous_1680748195
informahealthcare_journals_10_3109_03009742_2014_964305
crossref_primary_10_3109_03009742_2014_964305
PublicationCentury 2000
PublicationDate 2015-05-01
PublicationDateYYYYMMDD 2015-05-01
PublicationDate_xml – month: 05
  year: 2015
  text: 2015-05-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Scandinavian journal of rheumatology
PublicationTitleAlternate Scand J Rheumatol
PublicationYear 2015
Publisher Informa Healthcare
Publisher_xml – name: Informa Healthcare
References Castellino G (CIT0012) 2000
Fernandez R L F (CIT0009) 1994
Rees JD (CIT0013) 2006; 65
Santiago MB (CIT0005) 2007; 26
Handa R (CIT0011) 1999
Maksimowicz-McKinnon K (CIT0001) 2007; 56
Arend WP (CIT0007) 1990; 33
CIT0004
Morović-Vergles J. (CIT0006) 2006; 26
Lockshin MD (CIT0008) 2000; 43
Park MC (CIT0002) 2005; 34
Hughes GR (CIT0003) 1986; 13
Cohney S (CIT0010) 1995
References_xml – volume: 13
  start-page: 486
  year: 1986
  ident: CIT0003
  publication-title: J Rheumatol
  contributor:
    fullname: Hughes GR
– ident: CIT0004
  doi: 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
– start-page: 38478
  year: 1999
  ident: CIT0011
  publication-title: Rheumatology (Oxford)
  contributor:
    fullname: Handa R
– volume: 26
  start-page: 821
  issue: 5
  year: 2007
  ident: CIT0005
  publication-title: Clin Rheumatol.
  doi: 10.1007/s10067-006-0277-3
  contributor:
    fullname: Santiago MB
– volume: 34
  start-page: 284
  issue: 4
  year: 2005
  ident: CIT0002
  publication-title: Scand J Rheumatol.
  doi: 10.1080/03009740510026526
  contributor:
    fullname: Park MC
– start-page: 3523
  year: 1994
  ident: CIT0009
  publication-title: Lupus
  contributor:
    fullname: Fernandez R L F
– volume: 65
  start-page: 109
  year: 2006
  ident: CIT0013
  publication-title: Ann Rheum Dis.
  doi: 10.1136/ard.2004.034231
  contributor:
    fullname: Rees JD
– volume: 43
  start-page: 440
  year: 2000
  ident: CIT0008
  publication-title: Arthritis Rheum
  doi: 10.1002/1529-0131(200002)43:2<440::AID-ANR26>3.0.CO;2-N
  contributor:
    fullname: Lockshin MD
– start-page: 15157
  year: 1995
  ident: CIT0010
  publication-title: Am J Nephrol
  contributor:
    fullname: Cohney S
– volume: 33
  start-page: 1129
  issue: 8
  year: 1990
  ident: CIT0007
  publication-title: Arthritis Rheum.
  doi: 10.1002/art.1780330811
  contributor:
    fullname: Arend WP
– volume: 56
  start-page: 1000
  year: 2007
  ident: CIT0001
  publication-title: Arthritis Rheum.
  doi: 10.1002/art.22404
  contributor:
    fullname: Maksimowicz-McKinnon K
– volume: 26
  start-page: 773
  issue: 8
  year: 2006
  ident: CIT0006
  publication-title: Rheumatol Int.
  doi: 10.1007/s00296-005-0065-4
  contributor:
    fullname: Morović-Vergles J.
– start-page: 9717
  year: 2000
  ident: CIT0012
  publication-title: Lupus
  contributor:
    fullname: Castellino G
SSID ssj0004979
Score 2.1875944
Snippet Objectives: Previous studies have shown antiphospholipid antibodies (aPL) to be prevalent in primary systemic vasculitides; however, the possible clinical...
Previous studies have shown antiphospholipid antibodies (aPL) to be prevalent in primary systemic vasculitides; however, the possible clinical impact of aPL...
OBJECTIVESPrevious studies have shown antiphospholipid antibodies (aPL) to be prevalent in primary systemic vasculitides; however, the possible clinical impact...
SourceID proquest
crossref
pubmed
informaworld
informahealthcare
SourceType Aggregation Database
Index Database
Publisher
StartPage 211
SubjectTerms Adult
Antibodies, Anticardiolipin - immunology
Anticoagulants - therapeutic use
Antiphospholipid Syndrome - complications
Aortic Valve - surgery
Bicuspid Aortic Valve Disease
Carotid Artery Diseases - etiology
Coronary Artery Disease - etiology
Enzyme-Linked Immunosorbent Assay
Female
Femoral Artery
Heart Defects, Congenital - etiology
Heart Defects, Congenital - surgery
Heart Valve Diseases - etiology
Heart Valve Diseases - surgery
Heart Valve Prosthesis Implantation
Humans
Immunoglobulin G - immunology
Immunoglobulin M - immunology
Immunosuppressive Agents - therapeutic use
Ischemic Attack, Transient - etiology
Kidney Failure, Chronic - etiology
Lupus Coagulation Inhibitor - immunology
Male
Middle Aged
Peripheral Arterial Disease - etiology
Renal Artery
Retrospective Studies
Risk Factors
Stroke - etiology
Takayasu Arteritis - complications
Takayasu Arteritis - drug therapy
Takayasu Arteritis - immunology
Vision Disorders - etiology
Young Adult
Title Increased risk of vascular complications in Takayasu's arteritis patients with positive lupus anticoagulant
URI https://www.tandfonline.com/doi/abs/10.3109/03009742.2014.964305
https://www.ncbi.nlm.nih.gov/pubmed/25438797
https://search.proquest.com/docview/1680748195
Volume 44
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZCmMvo7tnNzQY7GG4i23Jsh-bZaUUWgZLoW9GkmVSOpyS2IX1bf9851jyLe1ufTHBwTmOv0_SOcfnfCLkfcLzQOso97hWymMsyD0Zw3hMpFKca8FzjY3CxyfR4Sk7OuNno9HPfndJqfb09a19JXdBFc4Brtgl-x_Itj8KJ-Az4AtHQBiO_4QxDG6sKTddhXhbWHqjVHwhL-QPuanqBH1dyIlqRo2uqmtysyVcV-bj9-qyQvVmMLmSuFt9Mcjhf9N1N4y8Ond5fOfTrpemAhd4kKo_gvDWZllP2l6ymbmWhVzKrf6IOVberKs6pz3_2k9I-Lwr_7NB6qCNCuvXelNaOJ16EMHY-de4KXeKPn44mJOtJqTjXjiYYP3eWh3YBtTtZSC0KqpoDY1hAR_bQ-GxKe-WvbYY0X5xj-wEIuF8THb2Z_PZQddcm1jBxubWbf8lmvh0m4GBf7Pr1G-X7bPYUsT9fVxT-zeLXfLQBSZ037LsERmZ4jG5f-xKL56Qi5ZsFMlGVzltyEYHZKPnBW3I9mFDW6rRhmoUqUYbqtGaanRAtafk9ODL4vOh53bq8DTz49LzkzgzzM-YEEZBxB5IYXCfBl9lLIwycDGjJIhgjQ-ZjrI4C4WIJCwueRhnEH_I8BkZF6vCvCAUwmGVB3nIdWJYoLQUPte-r2Np4iQw-YR4zfNNL60gSwqBLOKRNnikiEdq8ZgQcQOE1A2MzV-ujPtQpWWdQsvtfjd42Z8ufdfAmsJ0je_gZGFWFRiMUH0KX15PyHOLd_s3UJciFol4eXfDr8iDbki-JuNyXZk34DWX6q3j9S8Vt8Bk
link.rule.ids 315,786,790,27955,27956
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+risk+of+vascular+complications+in+Takayasu%27s+arteritis+patients+with+positive+lupus+anticoagulant&rft.jtitle=Scandinavian+journal+of+rheumatology&rft.au=Jordan%2C+NP&rft.au=Bezanahary%2C+H&rft.au=D%27Cruz%2C+DP&rft.date=2015-05-01&rft.pub=Informa+Healthcare&rft.issn=0300-9742&rft.eissn=1502-7732&rft.volume=44&rft.issue=3&rft.spage=211&rft.epage=214&rft_id=info:doi/10.3109%2F03009742.2014.964305&rft.externalDocID=964305
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-9742&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-9742&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-9742&client=summon